Macular degeneration

This Phase 3 trial tests an oral drug called gildeuretinol acetate (ALK 001) in 230 people aged 8 to 45 with Stargardt disease, a genetic condition that causes progressive vision loss. Participants take the drug or a placebo daily for 24 months. The goal is to see if the drug can…

This study is checking the long-term safety of an implant called OTX-TKI (axitinib) for people with wet age-related macular degeneration (AMD). The implant is placed in the eye and slowly releases medicine to control the disease. About 850 people who already completed two years o…

This study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a progressive form of age-related macular degeneration that causes vision loss. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3…

This study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…

This study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure h…

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can reduce the need for frequent eye injections while keeping vision stable. About 561 adults a…

This Phase 2 trial tests FWY003, an experimental drug, in 272 people with geographic atrophy (a form of advanced age-related macular degeneration). The goal is to see if different doses can slow the growth of damaged areas in the eye and preserve vision. Participants receive eith…

This study tests a gene therapy called AAVB-039 for Stargardt disease, an inherited condition that causes vision loss. About 75 adults with a specific gene mutation will receive a single injection under the retina. The main goal is to check safety, but researchers will also measu…

This Phase 2 trial tests whether adding APL-3007 to the existing drug Syfovre (pegcetacoplan) can better slow geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 240 adults aged 60 and older with the condition will receive e…

This study looks at switching people with wet age-related macular degeneration (AMD) to a higher dose (8 mg) of the drug aflibercept. The goal is to see if it can extend the time between eye injections while still controlling the disease. Researchers will compare injection interv…

This study tests an oral medication called BI 1815368 in 300 adults with center-involved diabetic macular edema, a common cause of vision loss in diabetes. Participants take tablets twice daily for about 11 months, and doctors compare vision changes between those on the drug and …

This early-stage trial tests whether transplanting lab-grown retinal cells into the eye is safe for people with geographic atrophy from dry age-related macular degeneration. Twenty participants aged 55 and older will receive a transplant of their own reprogrammed cells into one e…

This study tests a refillable eye implant (Port Delivery System) that slowly releases the drug ranibizumab to treat wet age-related macular degeneration. The implant is refilled every 36 weeks, potentially reducing the need for frequent eye injections. About 250 participants who …

This study tests a biodegradable eye implant called TO-O-1007 for geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The implant slowly releases medication over 6 months to slow disease progression. About 31 adults aged 50 and old…

This study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The m…

This study looks at 100 people with wet age-related macular degeneration (AMD) who have been getting regular eye injections with older drugs. They will switch to a newer drug called faricimab. The goal is to see if faricimab can extend the time between injections, meaning fewer t…

This study tests a single injection of CTx001 gene therapy into the eye for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The trial involves 75 participants and will monitor safety and whether the treatment can slow d…

This phase 3 trial tests whether a new drug called ABP 938 works as well as the approved treatment Eylea HD for wet age-related macular degeneration, a leading cause of vision loss. About 304 people aged 50 and older with untreated wet AMD will receive injections of either drug i…

This phase 3 trial tests two injectable drugs, pozelimab and cemdisiran, alone or together, to slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes central vision loss. About 975 participants will receive either the drugs or a…

This early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA) — a condition where parts of the retina stop working, leading to vision loss. The main goal is to check the drug's safety and tolerabili…

This Phase 2 trial tests an experimental drug called EYE103 (Restoret) in 160 people with wet age-related macular degeneration or macular edema from a branch retinal vein occlusion. Participants receive three eye injections of either a low or high dose of EYE103, spaced four week…

This study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss of a key…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment (SYFOVRE…

This study tests a new eye injection called KIO-104 for people with macular edema, a condition where fluid builds up in the eye and blurs vision. About 28 adults will receive multiple doses to see if the drug is safe and helps reduce swelling. The goal is to find a steroid-free o…

This phase 3 study tests a single injection of Ixo-vec gene therapy against standard aflibercept injections in 284 people with wet AMD. The goal is to see if Ixo-vec can maintain or improve vision while reducing the need for repeated eye injections. Participants must be at least …

This observational study will follow 300 people with wet age-related macular degeneration (nAMD) who receive aflibercept 8 mg injections as part of their routine care. Researchers want to see how well the drug improves vision and reduces retinal swelling over 12 months, and what …

This study is testing a refillable eye implant that delivers the drug ranibizumab to treat wet age-related macular degeneration (AMD). The main goal is to see if the implant affects the cells on the inner surface of the cornea. About 188 people with wet AMD will receive the impla…

This early-stage study tests a new treatment called C.001 for people with retinal diseases that cause vision loss, such as geographic atrophy and Stargardt disease. The treatment is given as a single injection into the eye. The main goal is to check if it is safe, and researchers…

This study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier studies for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The goal is to check long-term safety, including side effects and eye …

This study tests a gene therapy called Ixo-vec in the second eye of people with wet age-related macular degeneration (AMD) in both eyes. Fifteen adults aged 50 and older will receive a single injection in the second eye and be followed for about 5 years. The goal is to see if the…

This study tests whether a targeted laser treatment, called photothermal therapy, can slow the progression of intermediate age-related macular degeneration (AMD). About 240 people aged 60–90 with intermediate AMD will receive either the laser or a sham procedure. The main goal is…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a condition that can cause rapid vision loss. About 1,000 people who have already used the implant in earlier studies will…

This study tests a new medicine, EYP-1901, given as an eye injection to people with diabetic macular edema (DME), a condition that causes blurry vision in people with diabetes. The goal is to see if EYP-1901 works as well as the standard treatment (aflibercept) but with fewer inj…

This phase 3 trial tests EYP-1901, a new eye injection, against the standard treatment aflibercept for diabetic macular edema (DME), a condition that causes vision loss in people with diabetes. The study will enroll 240 participants and compare how well each drug improves vision …

This study tests the drug faricimab (Vabysmo) in 100 people aged 50+ with wet age-related macular degeneration who have a specific type of harmful material under their retina. The goal is to see if the drug can clear that material by week 16. Participants receive injections into …

This phase 3 trial tests an experimental drug called tabirafusp alfa (KSI-101) given as an eye injection for people with macular edema (swelling) caused by inflammation. The study will compare the drug to a sham (fake) injection in 600 participants to see if it improves vision an…

This Phase 3 trial tests whether people with wet age-related macular degeneration can use a home optical coherence tomography (OCT) device to guide when they need eye injections, instead of following a fixed schedule. 600 participants will either receive faricimab injections on a…

This study tests an experimental drug called tabirafusp alfa (KSI-101) given as an eye injection to treat macular edema (swelling in the back of the eye) caused by inflammation. About 300 adults with vision loss from this condition will receive either the drug or a sham injection…

This phase 3 trial tests whether adding surgery (vitrectomy, clot-busting drug, and gas bubble) to standard anti-VEGF injections can improve vision more than injections alone for people with a macular bleed from wet AMD. About 210 participants across Europe will be randomly assig…

This early-stage trial tests an experimental drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability in 18 volunteers aged 50 and older who have already received standa…

This study tests if a device that delivers mild electrical pulses to the eye (transcorneal electrical stimulation) can safely slow the progression of geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 70 people aged 60 and olde…

This study tests a device that delivers tiny electrical pulses through the eyelid to the back of the eye. The goal is to see if it can safely slow vision loss or improve sight in people with intermediate to advanced dry age-related macular degeneration. One hundred participants w…

This study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these blind spots. Ab…

This early-phase trial tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who have not improved with standard treatments. The drug is given by IV every two weeks for three doses. The study will check for safety and any signs that visi…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 714 adults aged 50-89 who currently need regular eye injections will receive either the gene therapy or standard treatment. The goal is to…

This Phase 3 trial tests a single injection of 4D-150, a gene therapy, in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can maintain or improve vision and reduce the need for standard anti-VEGF injections like Eylea. Participants …

This early-stage trial tests a gene therapy called ZVS106e for Stargardt disease, a genetic condition that causes vision loss. Nine participants will receive a single injection of the drug under their retina. The main goal is to check safety over 52 weeks, not yet to prove it wor…

This early-stage trial tests a single injection of a gene therapy called RTx-021 in the eye of people with Stargardt disease, a genetic condition that causes vision loss. Up to 18 participants will receive different doses to check safety and tolerability. Researchers will monitor…

This study tests whether an oral medication (doxycycline) can help people with wet age-related macular degeneration (AMD) who still have fluid under their retina despite standard eye injections. About 50 participants will receive either doxycycline or a placebo for several months…

This study tests a device called PRIMA, which is implanted under the retina to help people with inherited retinal diseases like Stargardt disease and retinitis pigmentosa see better. The trial will enroll 5 adults with severe central vision loss and measure improvements in visual…

This early-stage trial tests a gene therapy called OPGx-BEST1 for two rare inherited eye diseases that cause vision loss. About 10 adults will receive a single injection into one eye to see if it is safe and to find the best dose. The study will follow participants for 5 years to…

This Phase IIb trial tests a retinal implant (CPCB-RPE1) in 24 people with advanced dry age-related macular degeneration (geographic atrophy). Participants are randomly assigned to receive the implant or a sham procedure. The study measures changes in retinal sensitivity and visu…

This study tests a small telescope-like implant called SING IMT™ for people with advanced age-related macular degeneration (AMD) who have poor central vision in both eyes. The device is placed inside the eye during surgery, either replacing or sitting in front of the existing len…

This Phase 3 trial tests faricimab (Vabysmo) in 50 people with a type of age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if a personalized treat-and-extend schedule can keep the eye healthy while allowing longer breaks between i…

This early study tests a single injection of LX111 gene therapy in 10 people aged 50 or older with wet age-related macular degeneration (nAMD). The goal is to see if it is safe and can help control the disease, possibly reducing the need for frequent eye injections. Participants …

This Phase 3 trial tests a single injection of LX102 gene therapy under the retina for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. About 332 participants will receive either LX102 or standard aflibercept injections. The goal is to see i…

This study looks at how well a higher dose (8mg) of the drug Aflibercept (Eylea) works in the first two months for people with wet age-related macular degeneration, a leading cause of vision loss. Researchers will track fluid changes in the retina and vision improvements in 50 pa…

This study tests whether a 6-month online stationary cycling program can improve vision, physical function, and thinking skills in veterans aged 65-89 with intermediate age-related macular degeneration (AMD). Researchers will measure contrast sensitivity, night vision, and visual…

This study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…

This study tests a small telescope-like implant placed inside the eye to improve vision in people with end-stage age-related macular degeneration (AMD). 76 participants aged 55 and older will receive the implant and be followed for 12 months. The goal is to see if the device safe…

This early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. About 68 participants will take either ABF-101 or a placebo to see if it is wel…

This study tests whether GAL-101 eye drops can slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 110 adults aged 55 and older with early-stage atrophy will use the drops or a placebo daily for up to two years…

This study tests whether an oral drug called dimethyl fumarate (Tecfidera) can safely slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 90 adults aged 55–85 with geographic atrophy will take the drug for 12 m…

This study tests whether high-dose atorvastatin (a statin drug) can improve vision in people with intermediate age-related macular degeneration (AMD). Researchers will measure how quickly participants' eyes adjust to darkness and track changes in fatty deposits (drusen) in the re…

This study tests a new gene therapy called BS01 for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. The treatment uses a harmless virus to deliver a light-sensitive protein to the eye, aiming to restore or preserve vi…

This early-stage study tests a stem cell therapy called ASP7317 for people with geographic atrophy, the advanced form of dry age-related macular degeneration that causes central vision loss. The treatment involves injecting special cells under the retina to replace damaged ones. …

This study tests a new drug called IBI302, given as an eye injection, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can prevent further vision decline over 52 weeks. About 800 adults aged 50 and older with act…

This study tests whether taking krill oil capsules daily for 3 months can reduce drusen (fatty deposits) in the eyes of people with early or intermediate dry age-related macular degeneration (AMD). 24 adults will receive either krill oil or a placebo. The main goal is to see if t…

This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with this condition will take the drug for 12 month…

This early-phase trial tests a new gene therapy called VG801 for Stargardt disease, a genetic condition that causes vision loss. Fifteen people aged 6 and older will receive a single injection under the retina. The main goal is to check safety, but researchers will also measure a…

This study looks at how well a biosimilar drug called Yesafili works for people with wet age-related macular degeneration (AMD). About 54 participants will switch from the standard drug Eylea to Yesafili. Doctors will check vision and eye health to see if the biosimilar is a safe…

This study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots in people with geographic atrophy, an advanced form of dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the…

This early study tests a new gene therapy called ACDN-01 for people with Stargardt disease, a genetic condition that leads to progressive vision loss. The therapy is given as a one-time injection under the retina. The main goals are to check safety and find the right dose, with a…

This early study tests a special contact lens that slowly releases steroid medicine directly to the eye. It is for people with recurrent cystoid macular edema, a condition causing swelling in the back of the eye. The goal is to see if the lens is safe, comfortable, and a practica…

This study tests a new drug called SAR402663, given as a single injection into the eye, for people with wet age-related macular degeneration (AMD). The goal is to see if one dose can safely control the disease and reduce the need for frequent anti-VEGF injections. About 66 partic…

This early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision…

This early-stage trial tests whether transplanting lab-grown retinal cells (RPESC-RPE-4W) into the eye is safe for people with dry age-related macular degeneration (AMD), a leading cause of vision loss. About 18 adults over 55 will receive the transplant and be monitored for side…

This study tests whether taking a daily supplement of lutein, zeaxanthin, and fish oil for six months can improve thinking skills, eye health, and bone density in healthy adults. Researchers will enroll 80 people with low levels of a key eye pigment. Participants will take either…

This study tests whether faricimab (Vabysmo) injections given every 12-16 weeks can maintain stability in people with wet age-related macular degeneration (AMD) after an initial series of loading doses. The trial will enroll 40 adults over 50 with active wet AMD. The main goal is…

This early-stage trial tests an oral drug called MS-553 in 45 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. Participants take the drug daily for 8 weeks. The main goal is to check safety, but researchers will also measure changes…

This study looks at whether taking a supplement containing lutein, zeaxanthin, and meso-zeaxanthin can increase carotenoid levels in the skin, which may be linked to eye health. About 60 adults aged 18 to 50 will be randomly assigned to receive the supplement or a placebo for 12 …

This study tests an experimental oral tablet called HX9428 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial will enroll 198 adults aged 50–85 to check the drug's safety, how the body processes it, and whether it can improve eye…

This Phase 3 trial tests whether QA108 granules, a traditional Chinese medicine, can reduce drusen (fatty deposits) in the eyes of people with intermediate age-related macular degeneration. 400 participants will take the granules or a placebo for 24 weeks. The study aims to see i…

This study tests whether injecting a special blood product from umbilical cords into the eye can slow vision loss in people with dry age-related macular degeneration (AMD). The trial will involve 36 participants aged 65 and older with bilateral dry AMD. One eye will receive the i…

This pilot study is testing whether injections of a substance made from umbilical cord blood (called CB-PRP) can slow the progression of dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The study will enroll 36 people aged 65 and older wi…

This study compares three different NSAID eye drops (bromfenac, nepafenac, and diclofenac) to see which one best prevents cystoid macular edema, a type of swelling that can blur vision after cataract surgery. About 150 adults having cataract surgery will be randomly assigned to o…

This study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, sid…

This study evaluates PathFinder 1.0, a software that analyzes OCT images of the retina to detect macular abnormalities such as epiretinal membrane, dry age-related macular degeneration, and other retinal conditions. About 400 adults with and without macular issues will undergo st…

This study is testing a home-based eye-tracking system called AVIGA to see if it can detect when wet age-related macular degeneration (AMD) comes back. Sixty adults aged 50-99 who are being treated for wet AMD will use the AVIGA device at home, and its accuracy will be compared t…

This study tests a new eye imaging device (VG200D OCT) that takes detailed pictures of the retina. It compares these images to standard dye-based images (FA/ICGA) to see if the new device works just as well. About 30 adults with retina problems will take part. The goal is to see …

This study tests a special camera that takes detailed images of the retina using many wavelengths of light. Researchers hope it can find early signs of eye diseases like age-related macular degeneration, diabetic retinopathy, and glaucoma. About 1,000 adults in Melbourne, Austral…

This study tests a new device that uses special 'structured light' patterns to see if people with age-related macular degeneration (AMD) perceive them differently than those with healthy vision. The goal is to develop a test that can detect AMD earlier than current methods, befor…

This study is testing whether an AI system called DeepMSI AI can detect biomarkers of dry age-related macular degeneration (AMD) as accurately as experienced eye doctors. About 1,000 adults over 40, including those with and without AMD, will have their retinas imaged with a speci…

This study tests a new dye called MB-102 for taking pictures of the back of the eye (retina) to diagnose conditions like diabetic retinopathy and macular degeneration. About 10 adults with healthy or diseased eyes will receive both the new dye and a standard dye to compare safety…

This study is testing a new eye imaging device called the VG200D, which uses advanced technology to take detailed pictures of the eye. Researchers want to see if it works as well as a standard device for measuring parts of the eye in people with glaucoma, retina problems, corneal…

This study tests whether an AI tool (VeriSee) can help doctors detect two common causes of vision loss—diabetic retinopathy and age-related macular degeneration—earlier than standard exams. About 4,300 adults with diabetes or aged 50+ will be randomly assigned to AI-assisted scre…

This trial tests whether a community-based screening program using advanced eye imaging (OCT, fundus photography, and pressure checks) can prevent vision loss from age-related macular degeneration, diabetic retinopathy, and glaucoma better than simple vision tests alone. About 60…

This study looks at whether a visual rehabilitation program can ease anxiety and depression in people with advanced age-related macular degeneration (AMD). Twenty-two participants will attend five group sessions over 60 days, learning skills like coin recognition, using voice ass…

This early-phase trial tests whether a one-hour occupational therapy session—teaching strategies like better lighting, contrast, and organizational tools—can help people with age-related macular degeneration, diabetic retinopathy, or glaucoma manage their medications. Fifty parti…

This study tests whether 5 weekly sessions of eye exercises with real-time visual and audio feedback can improve how people with central vision loss use their peripheral vision. About 12 participants with bilateral central vision loss from macular degeneration will do saccadic an…

This study tests whether shifting text to healthier parts of the visual field can help people with age-related macular degeneration read faster and make fewer mistakes. About 108 participants with central vision loss will try two different text-remapping methods. The goal is to f…

This study tests a tiny gel-like insert placed in the tear duct that releases dexamethasone, a steroid, to reduce pain and swelling after vitreoretinal surgery. It compares the insert to standard steroid eye drops in 30 adults undergoing surgery for conditions like macular holes …

This study tests whether a gentle electrical brain stimulation, called a-tDCS, can make reading training more effective for people with age-related or juvenile macular degeneration. About 30 participants will do six reading training sessions while receiving either real or fake st…

This study looks at whether disulfiram (Antabuse), a drug used for alcohol use disorder, can improve vision in people with retinal degeneration (like macular degeneration or retinitis pigmentosa). Researchers believe it may calm overactive cells in the retina. The study involves …

This study follows 500 people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Participants receive avacincaptad pegol (IZERVAY) as part of their routine care. Researchers will collect data on treatment patterns, sid…

This study is creating a large collection of health information and biological samples (like blood, saliva, and eye tissue) from people with and without retinal diseases. Researchers aim to use this database to better understand conditions like age-related macular degeneration an…

This study screens people with eye diseases to see if they can join other research studies at the National Eye Institute. No treatment is given. Participants undergo eye exams, blood tests, and other procedures to diagnose or evaluate their condition. The goal is simply to determ…

This study follows 90 children and adults with Stargardt disease or similar inherited eye conditions to see how their vision changes over 2 years. Participants will have regular eye exams and imaging every 6 months. No treatment is given—the goal is to better understand the natur…

This study interviews 30 patients with wet age-related macular degeneration to understand their views on gene therapy. Researchers want to know if the benefits outweigh the risks of this irreversible treatment, and how patients make decisions about complex therapies. The goal is …

This study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …

This study collects skin, hair, blood, urine, or saliva samples from people with certain eye diseases (like macular degeneration) and from healthy volunteers. Researchers will turn these samples into stem cells in the lab to study how the diseases develop and to test potential ne…

This study is following 1,500 adults aged 55 and older to learn how early age-related macular degeneration (AMD) turns into the advanced form that can cause vision loss. Researchers will use eye imaging, genetic tests, and other measurements to find clues that predict progression…

This study watches how vision changes over two years in 50 people aged 65-90 with geographic atrophy (a form of dry age-related macular degeneration) who are already taking the drug pegcetacoplan. Researchers will use a special vision test that maps light sensitivity near damaged…

This study tests a special camera that takes super-detailed pictures of the back of the eye (the retina). The goal is to see if this technology can find eye diseases earlier than standard methods. Up to 1,000 people aged 12 and older, with or without eye disease, will have their …

This study tracks eye pressure in 100 people receiving a larger-volume injection of Aflibercept (0.07mL) for macular diseases like age-related macular degeneration. Researchers measure pressure right after the injection and at several time points, then check for any nerve damage …

This study compares immediate surgery versus waiting for vision to worsen in people with an epiretinal membrane (a thin layer of scar tissue on the eye's surface). It includes 400 adults with relatively good vision (20/40 or better) who have symptoms like blurring or distortion. …

This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment off…

This study observes 75 adults aged 55 and older with geographic atrophy (a late stage of age-related macular degeneration) to see how the condition progresses over a short time. Researchers will measure changes in eye structure and function, and explore links to genetics and life…

This study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Over two years, researchers will track vision changes, treatment schedules, and sa…

This study uses a special camera called an Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO) to take very detailed pictures of the retina in people with inherited retinal diseases like retinitis pigmentosa. Researchers will measure how the light-sensitive cells in the eye cha…

This study is creating a large database of eye measurements from 3,000 people with inflammatory eye diseases like diabetic retinopathy and age-related macular degeneration. Researchers will use advanced imaging to collect detailed information from both the front and back of the e…

This study follows 25 people aged 10 and older with Stargardt-like macular dystrophy (STDG3), a rare inherited eye disease that causes vision loss. Over three years, researchers will measure changes in the retina using eye exams, imaging, and vision tests. The goal is to understa…

This study collects fluid and blood samples from 260 people with age-related macular degeneration, diabetic retinopathy, or retinal detachment, plus healthy controls. Researchers will analyze proteins in these samples to identify markers that could help diagnose or track these ey…

This study aims to learn more about eye diseases by observing and providing standard care to up to 1,000 people over 5 years. Participants receive regular eye exams, tests, and treatments as needed. The goal is to better understand how eye diseases progress and are inherited, not…

This study looks at how well people with retinal diseases like retinitis pigmentosa and Stargardt's disease see in the dark. Researchers want to find out if measuring dark adaptation can help detect and track these conditions. Healthy volunteers and people with retinal disease ag…

This registry collects information from people with inherited retinal diseases, like retinitis pigmentosa and Stargardt disease. Participants share their symptoms, family history, and genetic test results online. The goal is to help researchers understand these rare diseases and …

This study uses special cameras to take ultra-detailed pictures of the back of the eye in people with retinal diseases like macular degeneration and retinitis pigmentosa. Researchers aim to develop new ways to diagnose and track these conditions by measuring cell density and func…

This study uses a special camera called an adaptive optics scanning laser ophthalmoscope to take incredibly detailed pictures of the retina, the light-sensitive layer at the back of the eye. Researchers will compare images from healthy people and those with eye diseases like Star…

This study is testing whether a simple vision screening program in general practice can help detect vision loss early in adults over 70 who have at least one chronic condition. Participants will have three vision tests done by their GP or nurse, then visit a collaborating opticia…

This study tests two simple ways to help people attend eye hospital appointments after being screened for age-related macular degeneration, diabetic retinopathy, or glaucoma. About 3,000 participants who need a follow-up visit will get either a text reminder, a home visit from a …

This study tests two advanced eye imaging techniques—central microperimetry and radial OCT—to see if they can more accurately measure the progression of geographic atrophy, a severe form of age-related macular degeneration that can lead to blindness. Researchers will follow 80 ad…

This study uses a special camera (adaptive optics) to take detailed pictures of the back of the eye in people with inherited retinal diseases. Researchers want to see how individual cells change over time and after treatments. About 200 participants aged 5 to 70 will be observed,…

This study looks at whether repeated eye injections of bevacizumab, a drug used for diabetic eye disease and other conditions, might affect heart health. Researchers will measure certain enzymes in the blood that are linked to heart disease risk. The study includes 180 adults age…

This study tests whether showing patients with diabetes short animated videos (in English or Spanish) about diabetic eye disease can improve their understanding and increase how often they return for follow-up eye exams. About 150 patients at Zuckerberg San Francisco General Hosp…

This study looks at 90 cataract patients who also have an epiretinal membrane (a thin layer on the retina). Researchers want to see if a special "functional" lens implant helps them see better without glasses compared to a standard lens. Participants will have their vision checke…

This study is testing new eye exams to see if they can better track early age-related macular degeneration (AMD). Researchers will measure how quickly the eye adapts to darkness in 150 healthy volunteers and people with early AMD. The goal is to find reliable ways to measure dise…

This study enrolls 25 people with severe retinal diseases like retinitis pigmentosa and Stargardt disease to test new ways of measuring visual function. Researchers will evaluate how well participants can perform various vision tests, such as navigating obstacles or detecting lig…

This study is collecting eye images from 1,000 adults aged 50 and older, with or without age-related macular degeneration (AMD), from up to 25 countries. The goal is to create a high-quality, diverse dataset that researchers can use to train artificial intelligence (AI) to screen…

This study looks back at 3,000 hospital patients to see if those who got a flu shot, took blood pressure meds (ACEI/ARB), antihistamines, or amantadine had better COVID-19 outcomes. Researchers want to know if these common treatments can reduce deaths or shorten hospital stays. N…

This study watches how early damage in age-related macular degeneration (AMD) grows over time. Researchers will use special eye scans to measure changes in the retina and see how they affect vision and daily life. The goal is to find better ways to detect and track the disease ea…

This prescreening study aims to identify up to 50 people with ABCA4-related retinopathy, including Stargardt disease, for possible participation in future ACDN-01 clinical trials. Participants will undergo genetic testing and various eye exams to confirm their condition. This is …

This study tests whether artificial intelligence can create simple summaries of eye doctor notes that are easier for patients to understand. About 460 English-speaking adults receiving eye care will get either standard notes or notes plus an AI-generated plain language summary. P…

This observational study seeks to define a new concept called 'visual frailty' in people aged 60 and older with advanced age-related macular degeneration (AMD). Researchers will measure vision, reading ability, mental health, and daily function in 20 participants to develop a vis…

This study is for people with age-related macular degeneration who have bleeding under the retina. Researchers want to see if the type of abnormal blood vessel affects how well vision recovers after a gas bubble procedure to move the blood. About 60 participants will be followed …

This study compares two surgical systems used for combined cataract and vitrectomy eye surgeries. The UNITY VCS system is being tested against the CONSTELLATION system to see which one surgeons find more efficient in real-world operating rooms. About 180 adults needing combined e…

This early-phase trial tests the safety of an oral drug called DC6001 in 76 healthy adults. Researchers will give single or multiple doses to see how the body handles the drug and if it causes side effects. This study does not involve people with Stargardt disease and is not desi…

This study gathers eye scan images from 180 people with healthy eyes or eye diseases like glaucoma and retinal disease. The goal is to collect data using a new optical coherence tomography (OCT) device called A10900. No treatment or medication is given. The information will help …

This study looks at whether special vision training can improve how people with central vision loss from macular degeneration see and move their eyes. Researchers will train 60 adults aged 18 to 89 with severe vision loss to better detect and discriminate visual patterns. The goa…

This study aims to understand the natural bacteria living on the surface of the eye in both healthy people and those with certain eye conditions. Researchers will collect eye swabs from 500 adults in middle Tennessee to build a database of what a normal eye microbiome looks like.…

This study tests a new 4D microscope-integrated OCT system for the first time in people during eye surgery. Researchers want to see if the system is easy to use, safe, and can clearly show eye structures. Five adults having eye surgery will take part. The goal is to improve imagi…

This study is a registry that collects health information from people in Switzerland who have neuromuscular disorders like SMA, DMD, BMD, and others. It aims to track symptoms, treatments, and outcomes over time to help researchers and doctors improve care. No new treatments are …

This study looks at whether sinusitis (sinus infection) is common in people with wet age-related macular degeneration (AMD) who need many eye injections. Researchers will screen 200 participants for sinusitis and treat it if found. They will then check if sinusitis treatment redu…

This study looks at how color vision changes over time in people with inherited retinal diseases (IRDs). Researchers will study 200 participants, including those with IRDs and healthy volunteers, to see how color vision loss relates to changes in the retina's structure. They are …

This study gathers standard eye movement and pupil data from 200 healthy volunteers, children, and people with eye or brain conditions using a VR headset called neos™. The headset shows images and tracks where participants look, how their pupils react, and how their eyes move. Th…

This study aims to find out why 20-40% of people with wet age-related macular degeneration (AMD) don't respond well to standard anti-VEGF injections. Researchers will collect fluid from inside the eye of 117 patients and compare those who respond well to treatment with those who …

This phase 3 trial is testing whether a person's genetic makeup influences how well they respond to two standard drugs for wet age-related macular degeneration: ranibizumab and bevacizumab. About 630 patients will receive one of the two drugs and be followed for three years. The …

This study tests a high-resolution imaging system to see tiny structures in the eye that routine tools cannot detect. Researchers will scan 1,200 people with various eye conditions and healthy volunteers. The goal is to better understand diseases like glaucoma, diabetes, and reti…

This study tests a special microscope that takes live 3D images inside the eye during surgery. It aims to help surgeons see better when treating conditions like retinal detachment, macular holes, and cataracts. About 262 people will take part, including healthy volunteers and sur…

This study tests a new, more comfortable eye camera (WiSLO) designed for children and adults. Researchers want to see if it takes better pictures and is less bothersome than current cameras. About 42 people with or without eye disease will have their eyes photographed with both t…

This observational study will follow 75 people aged 12 to 65 with Stargardt disease type 1, a genetic eye condition that causes vision loss. Researchers will use eye exams and imaging to track how the disease changes over time. The goal is to better understand the disease's progr…